Immunodeficiencies
ABSTRACT: Primary immunodeficiencies (PIDs) are uncommon, chronic and severe disorders of the immune system in which patients cannot mount a sufficiently protective immune response, leading to an increased susceptibility to infections. The treatment of choice for PID patients with predominant antibo...
- Autores:
-
Franco Restrepo, José Luis
Ballow, M.
Grimbacher, B.
Cunningham-Rundles, C.
Notarangelo, L.
Stein, M.
Helbert, M.
Gathmann, B.
Kindle, G.
Knight, A. K.
Ochs, H. D.
Sullivan, K.
- Tipo de recurso:
- Review article
- Fecha de publicación:
- 2009
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/33048
- Acceso en línea:
- https://hdl.handle.net/10495/33048
- Palabra clave:
- Anticuerpos Antibacterianos
Antibodies, Bacterial
Inmunodeficiencia Variable Común
Common Variable Immunodeficiency
Infecciones Bacterianas
Bacterial Infections
Bases de Datos Factuales
Databases, Factual
Inmunoglobulinas Intravenosas
Immunoglobulins, Intravenous
Síndromes de Inmunodeficiencia
Immunologic Deficiency Syndromes
Sistema de Registros
Registries
Infecciones Oportunistas
Opportunistic Infections
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id |
UDEA2_d3f388fc9f0c8addd978b06b37b43579 |
---|---|
oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/33048 |
network_acronym_str |
UDEA2 |
network_name_str |
Repositorio UdeA |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Immunodeficiencies |
title |
Immunodeficiencies |
spellingShingle |
Immunodeficiencies Anticuerpos Antibacterianos Antibodies, Bacterial Inmunodeficiencia Variable Común Common Variable Immunodeficiency Infecciones Bacterianas Bacterial Infections Bases de Datos Factuales Databases, Factual Inmunoglobulinas Intravenosas Immunoglobulins, Intravenous Síndromes de Inmunodeficiencia Immunologic Deficiency Syndromes Sistema de Registros Registries Infecciones Oportunistas Opportunistic Infections |
title_short |
Immunodeficiencies |
title_full |
Immunodeficiencies |
title_fullStr |
Immunodeficiencies |
title_full_unstemmed |
Immunodeficiencies |
title_sort |
Immunodeficiencies |
dc.creator.fl_str_mv |
Franco Restrepo, José Luis Ballow, M. Grimbacher, B. Cunningham-Rundles, C. Notarangelo, L. Stein, M. Helbert, M. Gathmann, B. Kindle, G. Knight, A. K. Ochs, H. D. Sullivan, K. |
dc.contributor.author.none.fl_str_mv |
Franco Restrepo, José Luis Ballow, M. Grimbacher, B. Cunningham-Rundles, C. Notarangelo, L. Stein, M. Helbert, M. Gathmann, B. Kindle, G. Knight, A. K. Ochs, H. D. Sullivan, K. |
dc.subject.decs.none.fl_str_mv |
Anticuerpos Antibacterianos Antibodies, Bacterial Inmunodeficiencia Variable Común Common Variable Immunodeficiency Infecciones Bacterianas Bacterial Infections Bases de Datos Factuales Databases, Factual Inmunoglobulinas Intravenosas Immunoglobulins, Intravenous Síndromes de Inmunodeficiencia Immunologic Deficiency Syndromes Sistema de Registros Registries Infecciones Oportunistas Opportunistic Infections |
topic |
Anticuerpos Antibacterianos Antibodies, Bacterial Inmunodeficiencia Variable Común Common Variable Immunodeficiency Infecciones Bacterianas Bacterial Infections Bases de Datos Factuales Databases, Factual Inmunoglobulinas Intravenosas Immunoglobulins, Intravenous Síndromes de Inmunodeficiencia Immunologic Deficiency Syndromes Sistema de Registros Registries Infecciones Oportunistas Opportunistic Infections |
description |
ABSTRACT: Primary immunodeficiencies (PIDs) are uncommon, chronic and severe disorders of the immune system in which patients cannot mount a sufficiently protective immune response, leading to an increased susceptibility to infections. The treatment of choice for PID patients with predominant antibody deficiency is intravenous immunoglobulin (Ig) replacement therapy. Despite major advances over the last 20 years in the molecular characterization of PIDs, many patients remain undiagnosed or are diagnosed too late, with severe consequences. Various strategies to ensure timely diagnosis of PIDs are in place, and novel approaches are being developed. In recent years, several patient registries have been established. Such registries shed light on the pathology and natural history of these varied disorders. Analyses of the registry data may also reveal which patients are likely to respond well to higher Ig infusion rates and may help to determine the optimal dosing of Ig products. Faster infusion rates may lead to improved convenience for patients and thus increase patient compliance, and may reduce nursing time and the need for hospital resources. Data from two recent studies suggest that Gamunex® and Privigen® are well tolerated at high infusion rates. Nevertheless, careful selection of patients for high infusion rates, based on co-morbid conditions and tolerance of the current infusion rate, is advisable. Based on the available data, intravenous Ig offers broad protection against encapsulated organisms. As vaccine trends change, careful monitoring of specific antibody levels in the general population, such as those against pneumococcal and meningococcal bacteria, should be implemented. |
publishDate |
2009 |
dc.date.issued.none.fl_str_mv |
2009 |
dc.date.accessioned.none.fl_str_mv |
2022-12-27T12:56:27Z |
dc.date.available.none.fl_str_mv |
2022-12-27T12:56:27Z |
dc.type.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.hasversion.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_dcae04bc |
dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ARTREV |
dc.type.local.spa.fl_str_mv |
Artículo de revisión |
format |
http://purl.org/coar/resource_type/c_dcae04bc |
status_str |
publishedVersion |
dc.identifier.citation.spa.fl_str_mv |
Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, Gathmann B, Kindle G, Knight AK, Ochs HD, Sullivan K, Franco JL. Immunodeficiencies. Clin Exp Immunol. 2009 Dec;158 Suppl 1(Suppl 1):14-22. doi: 10.1111/j.1365-2249.2009.04023.x. |
dc.identifier.issn.none.fl_str_mv |
0009-9104 |
dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10495/33048 |
dc.identifier.doi.none.fl_str_mv |
10.1111/j.1365-2249.2009.04023.x. |
dc.identifier.eissn.none.fl_str_mv |
1365-2249 |
identifier_str_mv |
Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, Gathmann B, Kindle G, Knight AK, Ochs HD, Sullivan K, Franco JL. Immunodeficiencies. Clin Exp Immunol. 2009 Dec;158 Suppl 1(Suppl 1):14-22. doi: 10.1111/j.1365-2249.2009.04023.x. 0009-9104 10.1111/j.1365-2249.2009.04023.x. 1365-2249 |
url |
https://hdl.handle.net/10495/33048 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
Clin Exp Immunol |
dc.rights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
dc.rights.accessrights.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.creativecommons.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.format.extent.spa.fl_str_mv |
9 |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
British Society for Immunology |
dc.publisher.group.spa.fl_str_mv |
Inmunodeficiencias Primarias |
dc.publisher.place.spa.fl_str_mv |
Oxford, Inglaterra |
institution |
Universidad de Antioquia |
bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/2/license_rdf https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/1/FrancoJose_2009_Immunodeficiencies.pdf https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/3/license.txt |
bitstream.checksum.fl_str_mv |
b88b088d9957e670ce3b3fbe2eedbc13 e54f4411565e008969dc345add65045e 8a4605be74aa9ea9d79846c1fba20a33 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad de Antioquia |
repository.mail.fl_str_mv |
andres.perez@udea.edu.co |
_version_ |
1812173103634055168 |
spelling |
Franco Restrepo, José LuisBallow, M.Grimbacher, B.Cunningham-Rundles, C.Notarangelo, L.Stein, M.Helbert, M.Gathmann, B.Kindle, G.Knight, A. K.Ochs, H. D.Sullivan, K.2022-12-27T12:56:27Z2022-12-27T12:56:27Z2009Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, Gathmann B, Kindle G, Knight AK, Ochs HD, Sullivan K, Franco JL. Immunodeficiencies. Clin Exp Immunol. 2009 Dec;158 Suppl 1(Suppl 1):14-22. doi: 10.1111/j.1365-2249.2009.04023.x.0009-9104https://hdl.handle.net/10495/3304810.1111/j.1365-2249.2009.04023.x.1365-2249ABSTRACT: Primary immunodeficiencies (PIDs) are uncommon, chronic and severe disorders of the immune system in which patients cannot mount a sufficiently protective immune response, leading to an increased susceptibility to infections. The treatment of choice for PID patients with predominant antibody deficiency is intravenous immunoglobulin (Ig) replacement therapy. Despite major advances over the last 20 years in the molecular characterization of PIDs, many patients remain undiagnosed or are diagnosed too late, with severe consequences. Various strategies to ensure timely diagnosis of PIDs are in place, and novel approaches are being developed. In recent years, several patient registries have been established. Such registries shed light on the pathology and natural history of these varied disorders. Analyses of the registry data may also reveal which patients are likely to respond well to higher Ig infusion rates and may help to determine the optimal dosing of Ig products. Faster infusion rates may lead to improved convenience for patients and thus increase patient compliance, and may reduce nursing time and the need for hospital resources. Data from two recent studies suggest that Gamunex® and Privigen® are well tolerated at high infusion rates. Nevertheless, careful selection of patients for high infusion rates, based on co-morbid conditions and tolerance of the current infusion rate, is advisable. Based on the available data, intravenous Ig offers broad protection against encapsulated organisms. As vaccine trends change, careful monitoring of specific antibody levels in the general population, such as those against pneumococcal and meningococcal bacteria, should be implemented.COL00124269application/pdfengBritish Society for ImmunologyInmunodeficiencias PrimariasOxford, Inglaterrainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTREVArtículo de revisiónhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by-nc-nd/4.0/ImmunodeficienciesAnticuerpos AntibacterianosAntibodies, BacterialInmunodeficiencia Variable ComúnCommon Variable ImmunodeficiencyInfecciones BacterianasBacterial InfectionsBases de Datos FactualesDatabases, FactualInmunoglobulinas IntravenosasImmunoglobulins, IntravenousSíndromes de InmunodeficienciaImmunologic Deficiency SyndromesSistema de RegistrosRegistriesInfecciones OportunistasOpportunistic InfectionsClin Exp ImmunolClinical and Experimental Immunology1422158Suplemento 1CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/2/license_rdfb88b088d9957e670ce3b3fbe2eedbc13MD52ORIGINALFrancoJose_2009_Immunodeficiencies.pdfFrancoJose_2009_Immunodeficiencies.pdfArtículo de revisiónapplication/pdf287691https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/1/FrancoJose_2009_Immunodeficiencies.pdfe54f4411565e008969dc345add65045eMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD5310495/33048oai:bibliotecadigital.udea.edu.co:10495/330482022-12-27 12:15:22.745Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.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 |